New neuropathological and neurochemical knowledge concerning Alzheimer's disease has led to an increasing interest in the possibility of treatment. Current concepts suggest two main avenues of treatment. First, a symptomatic modification of the mental defect might be feasible, for example, by drug treatment and, secondly, it may prove possible to modify the natural history of the disease by directly approaching the causative abnormality, when this is better understood. We shall refer to these as symptomatic and biological treatments, respectively.
The cholinergic hypothesis has been particularly fruitful in generating research.`'' This hypothesis suggested that the defect of learning and memory which is characteristic of the disease is due to defective synthesis of acetylcholine, a neurotransmitter involved in neural activity in the hypothalamus and in the neurons of the isodendritic core that project widely to the cortex. 4 This concept has been tested in a number of short trials of choline, lecithin and physostigmine.56 These 
SOURCE OF NEW TREATMENTS
Putative treatments for Alzheimer's disease have begun to emerge from current research into neurochemical and neurotransmitter abnormalities in the disease. As in any disease of unknown cause, possible treatments may also emerge from patient interest groups, from epidemiological studies, from treatments currently applied to other disorders, or from other sources. As has been the case in multiple sclerosis and motor neuron disease, adequate trials of these treatments are required to assess their potential benefits properly within the usual framework of toxicological, preclinical and clinical evaluation. So far, compounds used to test the cholinergic hypothesis have been naturally occurring foodstuffs, for example, choline and lecithin,6 or older compounds, such as physostigmine5 and tetrahydroacridine,9 that are no longer subject to patent agreements and therefore of less potential interest to the pharmaceutical industry.
DIAGNOSTIC CRITERIA AND SELECTION OF PATIENTS
Since no specific diagnostic test is available, the diagnosis of Alzheimer's disease remains a matter of clinical decision-making. This problem has been addressed by a working group which suggested criteria for definite, type can be used to identify responders in a patient population, and to determine the best dose of the compound studied. However, cross-over studies of individual patients will not address the question of the overall usefulness of a treatment in the generality of patients with Alzheimer's disease. Thus an attempt to establish both the effectiveness of a treatment and its optimum dosage in one trial is probably over-ambitious.
Sensitivity to change is an important aspect of any assessment procedure. The semi-quantitative methods of assessing mental state in current use were designed not for use in determining change or rate of change, but in quantifying the degree of mental abnormality. These scales are empirical and non-linear, and it is by no means appropriate to compare an individual's performance from one time to another in relation to any possible effect of a treatment. Thus these scales are not necessarily well-suited to longitudinal studies. Neuropsychological studies using the WAIS are more readily quantifiable but are intended more for diagnostic or educational assessment in patients with focal brain lesions than for clinical trials in a diffuse disorder in which testing will be necessary at multiple points in a relatively short period of time. 28 The WAIS was specifically designed not to be sensitive to short-term fluctuations in performance.
Although some neuropsychological test profiles include alternative test schedules, most have not been validated in longitudinal studies of drugs on mental state. Specific measures of verbal and non-verbal memory, immediate recall of random word lists and the effect of delay and distraction procedures are useful test procedures.29 Semantic memory tasks are also reliable in testing cognition, but there is no evidence that these tests are relevant to the experience of daily living. 30 Floor and ceiling effects are common problems in studies of dementia. Many demented patients achieve zero scores on standard tests but, if the tests that are chosen are too easy then some less severely disabled patients will achieve maximum scores. These problems emphasise the value of single case studies using appropriately designed measurement instruments. Direct indices of the effect of a compound are useful in confirming that it has pharmacological actions, for example, salivation or change in ocular accommodation are features of cholinergic effect outside the central nervous system. The ultimate measure of outcome must be better functioning in tasks of daily living, despite the initial concentration on more easily measured variables, such as learning and recall. New, properly validated scales of daily living abilities and performance are needed to cover the range of deficits encountered in patients with dementia, especially in patients with less severe cognitive defects.25 SAMPLE SIZE AND POWER CONSIDERATIONS Several factors will influence study duration and size. These include the chosen outcome of the study, the assessment instruments used, with their inherent variability, and the criteria for entry of subjects into the trial. Death is an unambiguous outcome of a progressive disorder, but will be less frequent than other outcomes and is a poor measure of benefit in a dementia. Outcomes based on the rate of deterioration of mental ability are dependent on the availability of sensitive measures of cognitive change. Currently, the variance of these measures is large and this is therefore an important factor in determining sample size. Preliminary studies to estimate this variability in the patient population to be studied may well be necessary to assure an adequate sample size. The heterogeneity of the patients studied will also influence power and sample size calculations. Separate analyses within homogeneous patient strata may be appropriate, but should be considered at the stage of trial design, rather than at the completion of the study.
